Skip to main content

Remote Job Finders (RJF)

AstraZeneca Makes Potential $10B+ China Commitment Despite Political Pressure

The investments come amid an ongoing insurance fraud probe into AstraZeneca’s former China head Leon Wang—and despite mounting pressure from President Trump for pharma companies to re-shore their manufacturing operations.

AbbVie Lawsuit Alleges That Partner Genmab “Misappropriated” Trade Secrets

AbbVie claims that Genmab turned a blind eye to trade secret theft allegedly used to support the development of ProfoundBio’s investigational antibody-drug conjugates. Genmab acquired ProfoundBio in May 2024.

J&J Joins Pharma Peers With $55B US Manufacturing Boost Following Trump’s Tariff Threats

Johnson & Johnson follows Eli Lilly in spending billions on U.S. manufacturing after President Donald Trump threatened major tariffs on pharmaceutical products. Pfizer has also promised a similar commitment.

Adaptimmune Raises ‘Substantial Doubt’ About Business Despite First-in-Class T Cell Therapy

Adaptimmune is rolling out its T cell therapy Tecelra for synovial sarcoma, recording $1.2 million in sales since its approval in August 2024. Nevertheless, it is pausing development of two oncology assets to save money.
Scroll to top